ConductScience.org, home

Paper33909232

Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.

Thein KZ and 17 others. Invest New Drugs, 2021. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. Papers, record 33909232. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33909232

Download JSON
Disease
cancer699 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.
PubMed
Journal
Invest New Drugs
PubMed
Year
2021
PubMed
Publication types
Clinical Trial, Phase I, Journal Article, Research Support, N.I.H., Extramural
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
0.39
iCite
Revised in PubMed
2026-01-27
PubMed

Authors18

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Thein KZKyaw Zinhttps://orcid.org/0000-0003-1518-1097
2Piha-Paul SASarina A
3Tsimberidou AApostolia
4Karp DDDaniel D
5Janku FFilip
6Zarifa AAbdulrazzak
7Shah JJatin
8Milton DRDenái R
9Bean SStacie
10McQuinn LLacey
11Gong JJing
12Colen RRivka
13Carter BWBrett W
14Subbiah VVivek
15Ogbonna DCDeby C
16Pant SShubham
17Meric-Bernstam FFunda
18Naing AAung

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
HydrazinesMajor topic
KaryopherinsMajor topic
NeoplasmsMajor topic
Receptors, Cytoplasmic and NuclearMajor topic
TriazolesMajor topic
Active Transport, Cell Nucleus
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Dose-Response Relationship, Drug
Female
Humans
Male
Maximum Tolerated Dose
Middle Aged
Topotecan
Exportin 1 Protein

Source PubMed

Download CSV of topics

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA016672NCI NIH HHSUnited StatesP30CA016672PubMed and NIHNIH RePORTER
UL1 TR003167NCATS NIH HHSUnited StatesUL1TR003167PubMed and NIHNIH RePORTER
(1UL1TR003167)Clinical and Translational Sciences Award (NIH/NCATS)UL1TR003167PubMed and NIHNIH RePORTER
(P30CA016672)MD Anderson Cancer Support Grant (NIH-NCI)P30CA016672PubMed and NIHNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT02419495Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in34705134Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.https://conductscience.org/library/papers/34705134

Source PubMed

Download CSV of comments and corrections

References29

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119097774New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer2009https://conductscience.org/library/papers/19097774PubMed
228810913Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.Breast Cancer Res2017https://conductscience.org/library/papers/28810913PubMed
329487219A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.Oncologist2018https://conductscience.org/library/papers/29487219PubMed
422773955The CRM1 nuclear export protein in normal development and disease.Int J Biochem Mol Biol2012https://conductscience.org/library/papers/22773955PubMed
524755012Clinical translation of nuclear export inhibitors in cancer.Semin Cancer Biol2014https://conductscience.org/library/papers/24755012PubMed
69384386CRM1 is responsible for intracellular transport mediated by the nuclear export signal.Nature1997https://conductscience.org/library/papers/9384386PubMed
725716206Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia.Blood2015https://conductscience.org/library/papers/25716206PubMed
819574837Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis.Neurosurgery2009https://conductscience.org/library/papers/19574837PubMed
919082467The expression of CRM1 is associated with prognosis in human osteosarcoma.Oncol Rep2009https://conductscience.org/library/papers/19082467PubMed
1027487856XPO1, therapeutic … and prognostic target in sarcomas.Oncoscience2016https://conductscience.org/library/papers/27487856PubMed
1127733172CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways.J Hematol Oncol2016https://conductscience.org/library/papers/27733172PubMed
1230112106Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents.Oncotarget2018https://conductscience.org/library/papers/30112106PubMed
1322833564NESdb: a database of NES-containing CRM1 cargoes.Mol Biol Cell2012https://conductscience.org/library/papers/22833564PubMed
1420003838Prognostic value of CRM1 in pancreas cancer.Clin Invest Med2009https://conductscience.org/library/papers/20003838PubMed
1518991627CRM1-mediated nuclear export of proteins and drug resistance in cancer.Curr Med Chem2008https://conductscience.org/library/papers/18991627PubMed
1631052304XPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma.J Clin Med2019https://conductscience.org/library/papers/31052304PubMed
1720651182Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know.AJR Am J Roentgenol2010https://conductscience.org/library/papers/20651182PubMed
1830996012A Phase II Trial of Selinexor (KPT-330) for Metastatic Triple-Negative Breast Cancer.Oncologist2019https://conductscience.org/library/papers/30996012PubMed
1925316614Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.J Hematol Oncol2014https://conductscience.org/library/papers/25316614PubMed
2031822399Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies.Gynecol Oncol2020https://conductscience.org/library/papers/31822399PubMed

See all 29 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
40313327Selinexor in Uveal Melanoma: A Hopeful Step or Just Another Hurdle?J Immunother Precis Oncol2025https://conductscience.org/library/papers/40313327PubMed
39816915Selinexor (KPT-330) in Combination with Immune Checkpoint Inhibition in Uveal Melanoma: A Phase 1B Trial.J Immunother Precis Oncol2025https://conductscience.org/library/papers/39816915PubMed
38783482The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials.Clin Transl Med2024https://conductscience.org/library/papers/38783482PubMed
35941226The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review.J Cancer Res Clin Oncol2023https://conductscience.org/library/papers/35941226PubMed
34944778Therapeutic Targeting of Exportin-1 in Childhood Cancer.Cancers (Basel)2021https://conductscience.org/library/papers/34944778PubMed
34559346Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.Invest New Drugs2022https://conductscience.org/library/papers/34559346PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
GPT2875PubTator's text mininghttps://conductscience.org/library/genes/2875NCBI Gene
SLC17A526503PubTator's text mininghttps://conductscience.org/library/genes/26503NCBI Gene
XPO17514PubTator's text mininghttps://conductscience.org/library/genes/7514NCBI Gene

Download CSV of genes

Drugs17

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
CYCLOPHOSPHAMIDECHEMBL1200796Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1200796ChEMBL
LEUCOVORIN CALCIUMCHEMBL1201138Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1201138ChEMBL
CARBOPLATINCHEMBL1351Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1351ChEMBL
ERIBULINCHEMBL1683590Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1683590ChEMBL
CAPECITABINECHEMBL1773Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1773ChEMBL
IPILIMUMABCHEMBL1789844Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1789844ChEMBL
FLUOROURACILCHEMBL185Derived from the trial1https://conductscience.org/library/drugs/CHEMBL185ChEMBL
NIVOLUMABCHEMBL2108738Derived from the trial1https://conductscience.org/library/drugs/CHEMBL2108738ChEMBL
PEMETREXEDCHEMBL225072Derived from the trial1https://conductscience.org/library/drugs/CHEMBL225072ChEMBL
PEMBROLIZUMABCHEMBL3137343Derived from the trial1https://conductscience.org/library/drugs/CHEMBL3137343ChEMBL
SELINEXORCHEMBL3545185Derived from the trial1https://conductscience.org/library/drugs/CHEMBL3545185ChEMBL
IRINOTECAN HYDROCHLORIDECHEMBL3989514Derived from the trial1https://conductscience.org/library/drugs/CHEMBL3989514ChEMBL
OXALIPLATINCHEMBL414804Derived from the trial1https://conductscience.org/library/drugs/CHEMBL414804ChEMBL
PACLITAXELCHEMBL428647Derived from the trial1https://conductscience.org/library/drugs/CHEMBL428647ChEMBL
OLAPARIBCHEMBL521686Derived from the trial1https://conductscience.org/library/drugs/CHEMBL521686ChEMBL
DOXORUBICINCHEMBL53463Derived from the trial1https://conductscience.org/library/drugs/CHEMBL53463ChEMBL
TOPOTECANCHEMBL84Derived from the trial1https://conductscience.org/library/drugs/CHEMBL84ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33909232

GET https://conductscience.org/api/papers/v1/33909232/references?page=2